Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 3 for:    mistral mitralix

MATTERS Study - Mistral Percutaneous Tricuspid Valve Repair FIM Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04071652
Recruitment Status : Recruiting
First Posted : August 28, 2019
Last Update Posted : March 4, 2021
Sponsor:
Information provided by (Responsible Party):
Mitralix

Brief Summary:

The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).

The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.


Condition or disease Intervention/treatment Phase
Tricuspid Valve Regurgitation Device: Mistral implantation Not Applicable

Detailed Description:

The study is designed to clinically demonstrate device acute safety and technical performance (Primary Endpoints) along with longer FU device safety and effectiveness evaluation (Secondary Endpoint).

The main objectives of the study are :

  • Evaluate the Acute safety of the implanted Mistral device post procedure and at 30 day follow up period.
  • Evaluate the long term Safety of the device.
  • Demonstrate effectiveness of the Mistral device in reducing TR.

Primary endpoints:

  • Safety: Acute safety. Rate of device related SAE including device related mortality, stroke, MI, cardiac tamponade, surgery for failed percutaneous repair and non-elective cardiovascular surgery to treat an adverse event. At discharge and 30 days.
  • Performance: Mistral Implantation rate of technical success (defined as successful device implantation with grasped chords from at least two leaflets.).

Secondary endpoints:

  • Safety: Safety at 3, 6 and 12 months. Rate of device related SAEs at 3, 6 and 12 months.
  • Effectiveness: TR reduction post-procedure, at discharge and 30 days, 3 and 6 months. Improved NYHA class, 6MWTdistance and KCCQ (quality of life) at 30 days, 3 and 6 months.

Relevant only for patients 11-20:

  • Safety: Safety at 3, 6, 12 and 24 months. Rate of device related SAEs at 3, 6, 12 and 24 months.
  • Effectiveness: TR reduction post-procedure, at discharge and 30 days, 3, 6, 12 and 24 months. Improved NYHA class, 6MWT distance and KCCQ (quality of Life) at 30 days, 3, 6, 12 and 24 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: MATTERS Study - Mistral Percutaneous Tricuspid Valve Repair FIM Study
Actual Study Start Date : August 8, 2017
Estimated Primary Completion Date : February 2023
Estimated Study Completion Date : February 2025

Arm Intervention/treatment
Experimental: Mistral

The Mistral is an investigational device intended for percutaneous trans-catheter repair in high risk for surgery individuals suffering from functional Tricuspid Regurgitation (TR).

The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.

Device: Mistral implantation
Mistral implant is implanted in the Tricuspid valve




Primary Outcome Measures :
  1. Safety: Acute safety. Rate of device related SAE [ Time Frame: Until hospital discharge - up to 5 days post procedure day ]
    including device related mortality, stroke, MI, cardiac tamponade, surgery for failed percutaneous repair and non-elective cardiovascular surgery to treat an adverse event

  2. Safety: Acute safety. Rate of device related SAE [ Time Frame: At 30 days post procedure ]
    including device related mortality, stroke, MI, cardiac tamponade, surgery for failed percutaneous repair and non-elective cardiovascular surgery to treat an adverse event

  3. Performance: Mistral Implantation rate of technical success [ Time Frame: Procedure ]
    defined as successful device implantation with grasped chords from at least two leaflets


Secondary Outcome Measures :
  1. Safety: Rate of device related SAE [ Time Frame: at 3 months post procedure ]
  2. Safety: Rate of device related SAE [ Time Frame: at 6 months post procedure ]
  3. Safety: Rate of device related SAE [ Time Frame: at 12 months post procedure ]
  4. Safety: Rate of device related SAE [ Time Frame: at 24 months post procedure ]
    Relevant only for patients 11-20

  5. Effectiveness: TR Grade reduction [ Time Frame: post procedure (1 hour after implant device has been implanted) ]
  6. Effectiveness: TR Grade reduction [ Time Frame: Until hospital discharge - up to 5 days post procedure day ]
  7. Effectiveness: TR Grade reduction [ Time Frame: at 30 days post procedure ]
  8. Effectiveness: NYHA class (categorization of heart failure extent) [ Time Frame: at 30 days post procedure ]
  9. Effectiveness: 6MWT distance [ Time Frame: at 30 days post procedure ]
  10. Effectiveness: KCCQ (Kansas City Cardiomyopathy Questionnaire) [ Time Frame: at 30 days post procedure ]
  11. Effectiveness: TR Grade reduction [ Time Frame: at 3 months post procedure ]
  12. Effectiveness: NYHA class (categorization of heart failure extent) [ Time Frame: at 3 months post procedure ]
  13. Effectiveness: 6MWT distance [ Time Frame: at 3 months post procedure ]
  14. Effectiveness: KCCQ (Kansas City Cardiomyopathy Questionnaire) [ Time Frame: at 3 months post procedure ]
  15. Effectiveness: TR Grade reduction [ Time Frame: at 6 months post procedure ]
  16. Effectiveness: TR Grade reduction [ Time Frame: at 12 months post procedure ]
    Relevant only for patients 11-20

  17. Effectiveness: TR Grade reduction [ Time Frame: at 24 months post procedure ]
    Relevant only for patients 11-20

  18. Effectiveness: NYHA class (categorization of heart failure extent) [ Time Frame: at 6 months post procedure ]
  19. Effectiveness: NYHA class (categorization of heart failure extent) [ Time Frame: at 12 months post procedure ]
    Relevant only for patients 11-20

  20. Effectiveness: NYHA class (categorization of heart failure extent) [ Time Frame: at 24 months post procedure ]
    Relevant only for patients 11-20

  21. Effectiveness: 6MWT distance [ Time Frame: at 6 months post procedure ]
  22. Effectiveness: 6MWT distance [ Time Frame: at 12 months post procedure ]
    Relevant only for patients 11-20

  23. Effectiveness: 6MWT distance [ Time Frame: at 24 months post procedure ]
    Relevant only for patients 11-20

  24. Effectiveness: KCCQ (Kansas City Cardiomyopathy Questionnaire) [ Time Frame: at 6 months post procedure ]
  25. Effectiveness: KCCQ (Kansas City Cardiomyopathy Questionnaire) [ Time Frame: at 12 months post procedure ]
    Relevant only for patients 11-20

  26. Effectiveness: KCCQ (Kansas City Cardiomyopathy Questionnaire) [ Time Frame: at 24 months post procedure ]
    Relevant only for patients 11-20



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has given signed study Informed Consent for participation prior to procedure.
  • Subject is ≥ 18 years of age or legal age in host country
  • Subject is willing and able to comply with all required follow-up evaluations
  • Genders eligible for the study: Both genders
  • Subject has TR of grade 3+ or more
  • Subject has left ventricular ejection fraction (LVEF) >20 %
  • Subject is of functional class 2 or more (NYHA)
  • The subject is high risk to undergo TV surgery as assessed and consented by a cardiac surgeon and an interventional cardiologist at the site (center heart team), and according to ESC/EACTS guidelines on the management of valvular heart disease.
  • Patients with Jugular and/or Femoral veins enabling catheterization with 12Fr catheters
  • Life expectancy ≥ 1 year

Exclusion Criteria:

  • Tricuspid Stenosis >mild
  • Tricuspid Subvalvular calcification or calcification of the chordae.
  • Subject has a history of a cerebral vascular accident (CVA) or transient ischemic attack (TIA) within the past 3 months.
  • Subject has a history of a myocardial infarction (MI) in the past 3 months
  • Subject has had a percutaneous interventional or other invasive cardiac or peripheral procedure ≤ 7 days of the index procedure
  • Subject has a history of, or has active endocarditis
  • Subject has echocardiographic evidence of intra-cardiac mass, thrombus, vegetation or soft-mobile deposits
  • Subject is in acute pulmonary edema.
  • Subject has hemodynamic instability requiring inotropic or mechanical support.
  • Subject has a known hypersensitivity or contraindication to anticoagulant or antiplatelet medication
  • Subject has renal insufficiency as evidenced by a serum Creatinine > 3.0mg/dL.
  • Subject has ongoing infection or sepsis
  • Subject has blood dyscrasias (leukopenia, acute anemia, thrombocytopenia, history of bleeding diathesis, or coagulopathy)
  • Subject has an active peptic ulcer or has had gastrointestinal (GI) bleeding within the past 3 months prior to the index procedure
  • Subject requires emergency surgery for any reason
  • Subject has a known allergy to Nitinol alloys, 316L\304 stainless steel.
  • Pregnant or lactating women.
  • Patients being dependent upon the sponsor or upon the investigator or upon the investigational site.
  • Subject has a known contrast media allergy
  • Presence of high degree atrio-ventricular block (2nd or 3rd degree A-V block), or the presence of tri-fascicular block
  • According to investigator on site the patient is suffering from a severe end stage disease (e.g. malignancy, severe pulmonary disease, liver disease, renal failure) and has a life expectancy of less than 1 year.
  • Contraindication for treatment with dual antiplatelet therapy for at least 3 months
  • Contraindication for TEE including trans-gastric views.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04071652


Contacts
Layout table for location contacts
Contact: Ira Yaron +972544402636 ira@mitralix.com

Locations
Layout table for location information
Israel
Haddassah Recruiting
Jerusalem, Kiryat Hadassah, Israel, 91120
Contact: Galina Levin    +972-2-6778914    lenving@hadassah.org.il   
The Chain Sheba Medical Center at Tel HaShomer Recruiting
Ramat Gan, Israel, 52621
Contact: Gita Veiber    +972 3 5303810    Gita.Veiber@sheba.health.gov.il   
Tel Aviv Sourasky Medical Center Recruiting
Tel Aviv, Israel, 6423906
Contact: Gali Hegler    03-6974924    galihp@tlvmc.gov.il   
Sponsors and Collaborators
Mitralix
Layout table for additonal information
Responsible Party: Mitralix
ClinicalTrials.gov Identifier: NCT04071652    
Other Study ID Numbers: CL-475
First Posted: August 28, 2019    Key Record Dates
Last Update Posted: March 4, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Tricuspid Valve Insufficiency
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases